<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436978</url>
  </required_header>
  <id_info>
    <org_study_id>NL71116.100.20</org_study_id>
    <nct_id>NCT04436978</nct_id>
  </id_info>
  <brief_title>What is the Optimal Antithrombotic Strategy in Patients Presenting With Acute Coronary Syndrome Having Atrial Fibrillation With Indication for Anticoagulants?</brief_title>
  <acronym>WOEST 3</acronym>
  <official_title>Safety and Efficacy of One Month Dual Antiplatelet Therapy Versus Standard Therapy With Oral Anticoagulant Plus P2Y12 Inhibitor and Short Course of Aspirin in Patients With Acute Coronary Syndrome or Percutaneous Coronary Intervention and Atrial Fibrillation: an Open-label, Multicentre, Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal antithrombotic management in patients with coronary artery disease (CAD) and&#xD;
      concomitant atrial fibrillation (AF) is unknown. Patients with AF are treated with oral&#xD;
      anticoagulation (OAC) to prevent ischemic stroke and systemic embolism and patients with&#xD;
      acute coronary syndrome (ACS) or those who undergo percutaneous coronary intervention (PCI)&#xD;
      are treated with dual antiplatelet therapy (DAPT), i.e. aspirin plus P2Y12 inhibitor&#xD;
      (clopidogrel), to prevent stent thrombosis (ST) and myocardial infarction (MI). Patients with&#xD;
      AF undergoing PCI were traditionally treated with triple antithrombotic therapy (TAT, i.e.&#xD;
      oral anticoagulation (OAC) plus aspirin and P2Y12 inhibitor) to prevent ischemic&#xD;
      complications. However, TAT doubles or even triples the risk of major bleeding complications.&#xD;
      More recently, several clinical studies demonstrated that omitting aspirin, a strategy known&#xD;
      as dual antithrombotic therapy (DAT) is safer compared to TAT with comparable efficacy.&#xD;
&#xD;
      However, pooled evidence from recent meta-analyses suggests that patients treated with DAT&#xD;
      are at increased risk of myocardial infarction (MI), stent thrombosis (ST) and even&#xD;
      cardiovascular (CV) death. Insights from the AUGUSTUS trial showed that aspirin added to OAC&#xD;
      and clopidogrel for 30 days, but not thereafter, resulted in fewer severe ischemic events.&#xD;
      This finding emphasizes the relevance of early aspirin administration on ischemic benefit,&#xD;
      also reflected in the current ESC guideline. However, because we consider the bleeding risk&#xD;
      of TAT unacceptably high, we propose to use a short course of DAPT (drop the OAC for 1&#xD;
      month). There is evidence from the BRIDGE study that a short period of omitting OAC is safe&#xD;
      in patients with AF. In this study, these patients are treated with DAPT that also prevents&#xD;
      stroke, albeit not as effective as OAC. Thus, by omitting OAC in the first month, we make&#xD;
      room for aspirin use for optimal prevention of myocardial infarction or stent thrombosis in&#xD;
      the first month after ACS or PCI.&#xD;
&#xD;
      The WOEST 3 trial is a multicentre, open-label, randomised controlled trial to investigate&#xD;
      the safety and efficacy of one month DAPT compared to standard therapy consisting of OAC and&#xD;
      P2Y12 inhibitor combined with aspirin up to 30 days. We hypothesise that the use of short&#xD;
      course DAPT is superior in bleeding and, secondary, non-inferior in preventing ischemic&#xD;
      events. The primary endpoint is clinically relevant bleeding (according to the International&#xD;
      Society of Thrombosis and Haemostasis definition) after one month. Secondary endpoints&#xD;
      include a composite of CV death, MI, ischemic stroke, ST, and systemic embolism after one&#xD;
      month, and one year follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2022</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2027</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>30 days</time_frame>
    <description>Major or clinically relevant non-major bleeding as defined by the International Society of Thrombosis and Haemostasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>30 days</time_frame>
    <description>Composite thrombotic end point of all-cause death, myocardial infarction, stent thrombosis, ischemic stroke, and systemic embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>1 year</time_frame>
    <description>Composite thrombotic end point of all-cause death, myocardial infarction, stent thrombosis, ischemic stroke, and systemic embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>1 year</time_frame>
    <description>Major or clinically relevant non-major bleeding as defined by the International Society of Thrombosis and Haemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net clinical benefit</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiovascular mortality, myocardial infarction, stent thrombosis, stroke, systemic embolism and clinically relevant bleeding as defined by the international society of thrombosis and haemostasis criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net clinical benefit</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiovascular mortality, myocardial infarction, stent thrombosis, stroke, systemic embolism and clinically relevant bleeding as defined by the international society of thrombosis and haemostasis criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life assessed by EuroQol-5D-5L questionnaire</measure>
    <time_frame>30 days, 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>NSTEMI - Non-ST Segment Elevation MI</condition>
  <condition>Bleeding</condition>
  <condition>Stroke</condition>
  <condition>Stent Thrombosis</condition>
  <condition>Embolism</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>First month DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>First month standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>First month DAPT</intervention_name>
    <description>One month of aspirin + P2Y12 inhibitor followed by 11 months of oral anticoagulants + P2Y12 inhibitor</description>
    <arm_group_label>First month DAPT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>First month standard therapy</intervention_name>
    <description>One month of oral anticoagulant + P2Y12 inhibitor + limited duration of aspirin as per international guidelines (during hospitalization or 7 days; up to 30 days for high thrombotic risk patients); followed by 11 months of oral anticoagulants + P2Y12 inhibitor</description>
    <arm_group_label>First month standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients â‰¥ 18 years&#xD;
&#xD;
          2. Presenting with ACS with elevated cardiac markers (CK/CK-MB, troponin) or undergoing&#xD;
             PCI&#xD;
&#xD;
          3. Documented or newly diagnosed non-valvular AF (&lt;72 hours after ACS) treated with OAC&#xD;
             or intention to treat &gt;1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of ischemic stroke&#xD;
&#xD;
          2. Mechanical prosthetic heart valve&#xD;
&#xD;
          3. &lt;3 months after venous thromboembolism&#xD;
&#xD;
          4. CHA2DS2-VASc &gt;5&#xD;
&#xD;
          5. Intracardiac thrombus&#xD;
&#xD;
          6. Rheumatic valve disease&#xD;
&#xD;
          7. Moderate/severe mitral valve stenosis&#xD;
&#xD;
          8. Conditions other than atrial fibrillation that require anticoagulation for which&#xD;
             direct oral anticoagulants will not be sufficient (e.g. prosthetic mechanical heart&#xD;
             valve, antiphospholipid syndrome)&#xD;
&#xD;
          9. History of known coagulopathy&#xD;
&#xD;
         10. Estimated Glomerular Filtration Rate &lt; 15 mL/min/1.73m^2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JurriÃ«n M ten Berg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Ziekenhuis Nieuwegein, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wilbert Bor, MD</last_name>
    <phone>+31 (0)88 320 1241</phone>
    <email>w.bor@antoniusziekenhuis.nl</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>J.M. ten Berg</investigator_full_name>
    <investigator_title>Professor dr.</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Atrial Flutter</keyword>
  <keyword>STEMI - ST Elevation Myocardial Infarction</keyword>
  <keyword>NSTEMI - Non-ST Segment Elevation MI</keyword>
  <keyword>Oral Anticoagulant</keyword>
  <keyword>NOAC - Novel Oral Anticoagulant</keyword>
  <keyword>DOAC - Direct Oral Anticoagulant</keyword>
  <keyword>DAPT - Dual Antiplatelet Therapy</keyword>
  <keyword>Antithrombotic Therapy</keyword>
  <keyword>Dual Therapy</keyword>
  <keyword>Triple Therapy</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Stroke</keyword>
  <keyword>Stent Thrombosis</keyword>
  <keyword>Systemic Embolism</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

